Please login to the form below

Not currently logged in
Email:
Password:

basal insulin

This page shows the latest basal insulin news and features for those working in and with pharma, biotech and healthcare.

Success for AZ, setback for Sanofi in type 1 diabetes

Success for AZ, setback for Sanofi in type 1 diabetes

There is a broad array of insulin products on the market, including short-acting versions used after meals and long-acting (basal) insulins designed to give background control of blood glucose, ... The decision is a blow to Sanofi’s hopes of rebuilding

Latest news

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1 ... It is also a key element in Sanofi’s plans to rebuild its diabetes

  • FDA starts review of Sanofi’s oral type 1 diabetes drug FDA starts review of Sanofi’s oral type 1 diabetes drug

    Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine

  • CHMP recommends Teva's generic version of Astellas' Advagraf CHMP recommends Teva's generic version of Astellas' Advagraf

    This would allow its use in combination with basal insulin, where the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.

  • Novo says real-world data backs its insulin switching Novo says real-world data backs its insulin switching

    EU-TREAT study shows Tresiba improved blood glucose control. Novo Nordisk's battle for supremacy in the basal insulin sector opened another front over the weekend as the firm presented ... It showed that switching to Tresiba (insulin from another basal

  • Sanofi to develop a mobile app for insulin patients Sanofi to develop a mobile app for insulin patients

    Will work with therapeutic companion software company Voluntis. Sanofi has expanded it alliance with a French therapeutic companion software company to develop a new mobile app for insulin patients. ... The tool, which Sanofi characterises as a

More from news
Approximately 0 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. ... We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan.

  • Going the distance Going the distance

    The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    ORBIT (Observational Registry for Basal Insulin Treatment) is a study focused on type 2 diabetes in China and the result of Sanofi's partnership with the CDS and George Institute for ... The company sees particular potential for Lyxumia as a combination

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics